Evidence map›Paper›PMID 41314548›Full record

ArticleJournal of substance use and addiction treatment2025

Gender-specific addiction research needed now more than ever: Reflections from 25 years of the NIDA Clinical Trials Network Gender Special Interest Group.

Aimee N C Campbell, A Kathleen Burlew, Constance Guille, Mia A Haidamus, Denise A Hien, Therese Killeen, Michelle R Lofwall, Margaret M Paschen-Wolff, Christi A Patten, Dawn E Sugarman and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of substance use and addiction treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aimee N C CampbellColumbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Drive, Unit 120, New York, NY, 10032, USA. Electronic address: anc2002@cumc.columbia.edu.
A Kathleen BurlewCenter for Addiction Research, University of Cincinnati College of Medicine, 3230 Eden Ave, Cincinnati, OH, 45267, USA.
Constance GuilleMedical University of South Carolina College of Medicine, Department of Psychiatry and Behavioral Sciences, 67 President St, Charleston, SC, 29425, USA.
Mia A HaidamusMcLean Hospital, 115 Mill Street, Belmont, MA, 02115, USA.
Denise A HienRutgers University Center of Alcohol & Substance Use Studies, 607 Allison Road, Piscataway, NJ, USA.
Therese KilleenMedical University of South Carolina College of Medicine, Department of Psychiatry and Behavioral Sciences, 67 President St, Charleston, SC, 29425, USA.
Michelle R LofwallUniversity of Kentucky College of Medicine, Departments of Behavioral Science and Psychiatry, Center on Drug and Alcohol Research, 845 Angliana Avenue, Lexington, KY, 40508, USA.
Margaret M Paschen-WolffColumbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Drive, Unit 120, New York, NY, 10032, USA.
Christi A PattenMayo Clinic, Department of Psychiatry and Psychology, 200 First ST SW, Rochester, MN, 55901, USA.
Dawn E SugarmanMcLean Hospital, 115 Mill Street, Belmont, MA, 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
T John WinhusenCenter for Addiction Research, University of Cincinnati College of Medicine, 3230 Eden Ave, Cincinnati, OH, 45267, USA.
Ludmila N BakhirevaUniversity of New Mexico Health and Health Sciences Center, College of Pharmacy, MSC09 5360, 1 University of New Mexico, Albuquerque, NM, 87131, USA.
Amy M LoreeHenry Ford Health, Center for Health Policy & Health Services Research, 1 Ford Place, Detroit, MI, 48202, USA.
Shayna MazelNew York University Grossman School of Medicine, 180 Madison Avenue, New York, NY, 10016, USA.
Shelly F GreenfieldMcLean Hospital, 115 Mill Street, Belmont, MA, 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Suicide Prediction and Prevention for People at Risk for Opioid Use DisorderUG1DA040316 · NIDA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI GAVIN BART · 2015 to 2026
$42.2M
Southern Consortium Node of the Clinical Trials Network (Varenicline)UG1DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, Kelly S. Barth · 2015 to 2026
$24.8M
Southwest Clinical Trials Node: Clinical Research and Practice to Address Substance Use in Diverse, Rural, and Underserved PopulationsUG1DA049468 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI MARIA ADELA GRANDO, Kimberly Page · 2019 to 2026
$12.5M
Increasing Women's Engagement in Medication Treatment for Opioid Use Disorder through Digital InterventionK23DA050780 · NIDA · MCLEAN HOSPITAL · PI SUGARMAN, DAWN E · 2020 to 2024
$938k
NIDA NIH HHS K23 DA050780NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013727NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1 DA040316NIDA NIH HHS UG1 DA049468
6 · The paper itself

Abstract

Despite rising rates of substance use disorders (SUD) in women and the narrowing of the SUD gender prevalence ratio in the U.S., large knowledge gaps in gender-specific treatment remain. The NIDA Clinical Trials Network (CTN) Gender Special Interest Group (GSIG) has provided opportunities to bring the gender lens to national multi-site clinical trials, ancillary studies, secondary data analyses, recommendations for data collection and demographic data, among other contributions to CTN and the SUD treatment field. This commentary provides background on gender differences and the knowledge gap, a history of the CTN GSIG, and its accomplishments via gender specific trials and key secondary analyses. The commentary will close with future directions and recommendations for research including improving the inclusion of intersectional identities in recruitment reach and analyses, reproductive health, pregnant and parenting people, and methodological considerations for clinical trials to enhance capacity to collect and understand data related to gender.

Indexed as

Addiction treatmentGenderPerinatalSexSubstance use disorders

Identifiers

PMID41314548
PMCPMC12853563

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.